New therapeutic targets for human placental angiogenesis diseases
A large number of publications have described impaired angiogenesis and vasculogenesis present in the feto-placental circulation after pregnancy diseases such as pre-eclamptic pregnancies, gestational diabetes, and intrauterine growth restriction, among others. Results suggest impaired secretion and...
Saved in:
Superior document: | Frontiers Research Topics |
---|---|
: | |
Year of Publication: | 2015 |
Language: | English |
Series: | Frontiers Research Topics
|
Physical Description: | 1 electronic resource (113 p.) |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993548063204498 |
---|---|
ctrlnum |
(CKB)3710000000612065 (oapen)https://directory.doabooks.org/handle/20.500.12854/54618 (EXLCZ)993710000000612065 |
collection |
bib_alma |
record_format |
marc |
spelling |
Carlos Alonso Escudero auth New therapeutic targets for human placental angiogenesis diseases Frontiers Media SA 2015 1 electronic resource (113 p.) text txt rdacontent computer c rdamedia online resource cr rdacarrier Frontiers Research Topics A large number of publications have described impaired angiogenesis and vasculogenesis present in the feto-placental circulation after pregnancy diseases such as pre-eclamptic pregnancies, gestational diabetes, and intrauterine growth restriction, among others. Results suggest impaired secretion and activity of pro-angiogenic factors such as vascular endothelial growth factor (VEGF), interleukin 8 (IL-8), adenosine and nitric oxide, associates with compromised secretion and activity of anti-angiogenic factors such as soluble receptor of VEGF (sFlt-1), thrombospondin 2, endostatin among others. More recent evidences include the participation of endothelial progenitor cells (EPC), which circulating number is reduced infeto-placental circulation in pregnancies such as pre-eclampsia. Despite this knowledge, therapies for placental angiogenesis recovery during pathological pregnancies are far to be tested. However, from the cardiovascular field, it has been described the administration of EPC, alone or used as gene-transfer therapy; or it has been described the potential role of statins (HMGCoA inhibitors), or angiotensin-converter enzyme (ACE) inhibitors for enhancing angiogenesis. Finally, feto-placental tissue is an exceptional source of progenitor and stem cells, which could be used for treated other human diseases such as stroke, myocardial infarction, hypertension, or even cancer. In this research topic, authors highlight physiopatological and clinical importance of the impaired placental angiogenesis, and suggest potential targets for developing innovative therapies. English Angiogenesis Placenta therapy fetal programming Pregnancy Diseases 2-88919-461-2 |
language |
English |
format |
eBook |
author |
Carlos Alonso Escudero |
spellingShingle |
Carlos Alonso Escudero New therapeutic targets for human placental angiogenesis diseases Frontiers Research Topics |
author_facet |
Carlos Alonso Escudero |
author_variant |
c a e cae |
author_sort |
Carlos Alonso Escudero |
title |
New therapeutic targets for human placental angiogenesis diseases |
title_full |
New therapeutic targets for human placental angiogenesis diseases |
title_fullStr |
New therapeutic targets for human placental angiogenesis diseases |
title_full_unstemmed |
New therapeutic targets for human placental angiogenesis diseases |
title_auth |
New therapeutic targets for human placental angiogenesis diseases |
title_new |
New therapeutic targets for human placental angiogenesis diseases |
title_sort |
new therapeutic targets for human placental angiogenesis diseases |
series |
Frontiers Research Topics |
series2 |
Frontiers Research Topics |
publisher |
Frontiers Media SA |
publishDate |
2015 |
physical |
1 electronic resource (113 p.) |
isbn |
2-88919-461-2 |
illustrated |
Not Illustrated |
work_keys_str_mv |
AT carlosalonsoescudero newtherapeutictargetsforhumanplacentalangiogenesisdiseases |
status_str |
n |
ids_txt_mv |
(CKB)3710000000612065 (oapen)https://directory.doabooks.org/handle/20.500.12854/54618 (EXLCZ)993710000000612065 |
carrierType_str_mv |
cr |
hierarchy_parent_title |
Frontiers Research Topics |
is_hierarchy_title |
New therapeutic targets for human placental angiogenesis diseases |
container_title |
Frontiers Research Topics |
_version_ |
1796649042998984704 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02550nam-a2200325z--4500</leader><controlfield tag="001">993548063204498</controlfield><controlfield tag="005">20231214132941.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202102s2015 xx |||||o ||| 0|eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)3710000000612065</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/54618</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)993710000000612065</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Carlos Alonso Escudero</subfield><subfield code="4">auth</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">New therapeutic targets for human placental angiogenesis diseases</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="b">Frontiers Media SA</subfield><subfield code="c">2015</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (113 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Frontiers Research Topics</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">A large number of publications have described impaired angiogenesis and vasculogenesis present in the feto-placental circulation after pregnancy diseases such as pre-eclamptic pregnancies, gestational diabetes, and intrauterine growth restriction, among others. Results suggest impaired secretion and activity of pro-angiogenic factors such as vascular endothelial growth factor (VEGF), interleukin 8 (IL-8), adenosine and nitric oxide, associates with compromised secretion and activity of anti-angiogenic factors such as soluble receptor of VEGF (sFlt-1), thrombospondin 2, endostatin among others. More recent evidences include the participation of endothelial progenitor cells (EPC), which circulating number is reduced infeto-placental circulation in pregnancies such as pre-eclampsia. Despite this knowledge, therapies for placental angiogenesis recovery during pathological pregnancies are far to be tested. However, from the cardiovascular field, it has been described the administration of EPC, alone or used as gene-transfer therapy; or it has been described the potential role of statins (HMGCoA inhibitors), or angiotensin-converter enzyme (ACE) inhibitors for enhancing angiogenesis. Finally, feto-placental tissue is an exceptional source of progenitor and stem cells, which could be used for treated other human diseases such as stroke, myocardial infarction, hypertension, or even cancer. In this research topic, authors highlight physiopatological and clinical importance of the impaired placental angiogenesis, and suggest potential targets for developing innovative therapies.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Angiogenesis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Placenta</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">therapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">fetal programming</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Pregnancy Diseases</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">2-88919-461-2</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-12-15 05:37:32 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2016-03-17 15:52:20 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338721480004498&Force_direct=true</subfield><subfield code="Z">5338721480004498</subfield><subfield code="b">Available</subfield><subfield code="8">5338721480004498</subfield></datafield></record></collection> |